SCHEMBL31326535

SCHEMBL31326535

CC(C)(C)OC(=O)C[C@@H](Cc1ccccn1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRA P18433 1/20 0.51
CYP1A2 P05177 3/20 0.42
FDPS P14324 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 2/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CPA1 P15085 2/20 0.38
CPB1 P15086 1/20 0.38
CPA3 P15088 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21978634 1.00 PTPRA (0.51) PTPRACYP1A2FDPSSMN1; SMN2TSHR
SCHEMBL21978636 1.00 PTPRA (0.51) PTPRACYP1A2FDPSSMN1; SMN2TSHR
SCHEMBL21978581 0.87 HDAC6 (0.46) PTPRACYP1A2FDPSSMN1; SMN2TSHR
SCHEMBL21978531 0.87 HDAC6 (0.46) PTPRACYP1A2FDPSSMN1; SMN2TSHR
SCHEMBL27954184 0.85 PTPRA (0.47) PTPRACYP1A2FDPSSMN1; SMN2TSHR
SCHEMBL30191609 0.81 KMT2A (0.41) SMN1; SMN2CA2CA9CPA1CPB1
SCHEMBL22035812 0.81 KMT2A (0.41) SMN1; SMN2CA2CA9CPA1CPB1
SCHEMBL1704171 0.80 CPA1 (0.60) CYP1A2CA2CA9CPA1CPB1
SCHEMBL1704913 0.80 CPA1 (0.60) CYP1A2CA2CA9CPA1CPB1
SCHEMBL1915766 0.80 CPA1 (0.60) CYP1A2CA2CA9CPA1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113166114-B Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders 诺华股份有限公司 2025-01-03 CN disclosed